M I Larg1,2, E Barbus1,2, K Gabora1,2, C Pestean1,2, M Cheptea1, D Piciu1,2. 1. "Prof. Dr. Ion Chiricuta" Oncology Institute - Nuclear Medicine Department, Cluj-Napoca, Romania. 2. "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Abstract
AIM: Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) become an important tool in oncology by combining the metabolic information from 18F-FDG PET with the morphological information of CT. The main objective of this study was to assess the diagnostic value of PET/CT in patients with differentiated thyroid carcinoma (DTC). MATERIAL AND METHODS: We analyzed 173 PET/CT scans of patients with DTC presenting elevated thyroglobulin (Tg) levels, negative Tg-antibodies levels, negative Iodine-131 whole-body scanning (I-131 WBS) and without any signs of clinical or other imaging technique for tumor recurrence/metastases. RESULTS: PET/CT scans were positive in 38% of cases (65/173). The sensitivity, specificity, positive predictive values and the accuracy of PET/CT imaging were 88.09%, 98.6%, 93.1% respectively 96.53%. After the PET/CT scan 29 patients underwent surgery, 24 of them continued radio-iodine therapy, 5 patients initiated tyrosine kinase inhibitors treatment and external radiotherapy. CONCLUSION: 18F-FDG PET/CT is a valuable imaging technique which has the capability of identifying those cases of thyroid recurrence/metastases with elevated Tg levels and negative I-131 WBS. The treatment strategy was changed in 89.2% cases of positive PET/CT scans which shows us that 18F-FDG PET/CT imaging should be integrated into the follow-up programs for DTC patients.
AIM: Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) become an important tool in oncology by combining the metabolic information from 18F-FDG PET with the morphological information of CT. The main objective of this study was to assess the diagnostic value of PET/CT in patients with differentiated thyroid carcinoma (DTC). MATERIAL AND METHODS: We analyzed 173 PET/CT scans of patients with DTC presenting elevated thyroglobulin (Tg) levels, negative Tg-antibodies levels, negative Iodine-131 whole-body scanning (I-131 WBS) and without any signs of clinical or other imaging technique for tumor recurrence/metastases. RESULTS: PET/CT scans were positive in 38% of cases (65/173). The sensitivity, specificity, positive predictive values and the accuracy of PET/CT imaging were 88.09%, 98.6%, 93.1% respectively 96.53%. After the PET/CT scan 29 patients underwent surgery, 24 of them continued radio-iodine therapy, 5 patients initiated tyrosine kinase inhibitors treatment and external radiotherapy. CONCLUSION: 18F-FDG PET/CT is a valuable imaging technique which has the capability of identifying those cases of thyroid recurrence/metastases with elevated Tg levels and negative I-131 WBS. The treatment strategy was changed in 89.2% cases of positive PET/CT scans which shows us that 18F-FDG PET/CT imaging should be integrated into the follow-up programs for DTC patients.
Authors: Richard J Robbins; Qiang Wan; Ravinder K Grewal; Roland Reibke; Mithat Gonen; H William Strauss; R Michael Tuttle; William Drucker; Steven M Larson Journal: J Clin Endocrinol Metab Date: 2005-11-22 Impact factor: 5.958
Authors: Andries H Groen; Mariëlle S Klein Hesselink; John T M Plukker; Wim J Sluiter; Anouk N A van der Horst-Schrivers; Adrienne H Brouwers; Eef G W M Lentjes; Anneke C Muller Kobold; Thera P Links Journal: Clin Endocrinol (Oxf) Date: 2016-09-28 Impact factor: 3.478
Authors: Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky Journal: Thyroid Date: 2016-01 Impact factor: 6.568
Authors: A Kukulska; J Krajewska; Z Kołosza; E Paliczka-Cies Lik; Z Puch; E Gubała; A Król; M Kalemba; A Kropin Ska; B Jarząb Journal: Eur J Endocrinol Date: 2016-08-10 Impact factor: 6.664
Authors: M Sahin; B I Aydoğan; E Özkan; R Emral; S Güllü; M F Erdogan; D Çorapçıoğlu Journal: Acta Endocrinol (Buchar) Date: 2021 Jul-Sep Impact factor: 0.877
Authors: Katalin Gabora; Ovidiu Bălăcescu; Adrian Trifa; Ana Maria Morariu; Bogdan Pop; Simona Vişan; Bogdan Fetica; Andra Piciu; Doina Piciu Journal: Med Pharm Rep Date: 2022-07-26
Authors: Sasha R Howard; Sarah Freeston; Barney Harrison; Louise Izatt; Sonali Natu; Kate Newbold; Sabine Pomplun; Helen A Spoudeas; Sophie Wilne; Tom R Kurzawinski; Mark N Gaze Journal: Endocr Relat Cancer Date: 2022-09-07 Impact factor: 5.900